About Us

Intensity Therapeutics is a clinical stage biotechnology company focused on treating both the macro and micro aspects of solid tumor cancers. Our lead product candidate, INT230-6, a multi-agent product, enables improved recognition of cancer by the immune system when injected directly into the tumor.

Portage shareholders own approximately 10% of the company. Portage also serves as the Chief Medical Officer, provides project management support and holds a non-executive seat on the Board of Directors.

Pipeline

COMPANY
ASSET
INDICATION
STAGE

Logo Intensity

ASSET
INT230-6
INTXX
INDICATION
Solid Tumor
Solid Tumor
STAGE
Phase I/II
Preclinical

Programs

Intensity Therapeutics is developing novel product candidates using its DfuseRxSM technology platform, which rapidly identifies tissue dispersions and cell-penetrating anti-cancer formulations for different tumor types. In partnership with the National Cancer Institute, it has created this patented technology to inject tumor antigens and create a vaccine-like effect in a range of solid tumors.

The company is evaluating INT230-6, an effective formulation that consists of cell penetration enhancers matched with potent anti-cancer agents. By injecting

directly into the tumor, this multi-agent approach efficiently enables the destruction of primary tumors, and creates a strong, adaptive immune response, equipping the immune system to identify and destroy metastases. The compound has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for triple negative breast cancer and has reported preliminary safety/efficacy data from a Phase 1/2 study for the treatment of refractory solid tumors. In addition, Intensity has announced a clinical collaboration with Merck to study its lead drug in combination with pembrolizumab.

Leadership

Mr. Bender has over 25 years of biopharmaceutical leadership …

Vice President and Chief Medical Officer

Dr. Walters has over 20 years of leadership and expertise in …

Prior to joining Intensity Therapeutics, John was Director of Costing …

Board of Directors

Mr. Bender has over 25 years of biopharmaceutical leadership …

Dr. Mark A Goldberg recently served as president and COO of PAREXEL …

Board Member

Dr. Declan Doogan has over 30 years of industry experience in both major …

Board Member

Dr. Emer Leahy received her PhD in Neuropharmacology from University …

Clinical Advisory Board

Dr. Viau is President of CJV Toxicology, LLC and a member of PharmaDirections…

Clinical Advisory Board Member

Dr. Riccardo Lencioni was most recently professor of clinical …

Clinical Advisory Board Member

Dr. Sznol is currently professor of internal medicine at Yale University …

Clinical Advisory Board Member

Dr. Berzofsky pioneered characterization of B and T cell epitopes and their …